Study S001515

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic of SYH9017 in Chinese Participants With Overweight and Obesity Following Single and Multiple Doses

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06830343
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 66
Start: 2025-02-27
Primary completion: 2026-08-01
Lead sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Conditions: Overweight or Obesity
Interventions: DRUG:SYH9017; DRUG:Placebo; DRUG:Wegovy ®
Results posted: FALSE

Registered primary outcomes

Incidence of AEs following single-dose administration of SYH9017 Description: [up to 49 days after the dosing]
Incidence of AEs following multiple doses administration of SYH9017AEs of SYH 9017 following multiple doses [up to 140 days after the last dosing]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.